organization · Reporting owner
Decheng Capital China Life Sciences USD Fund III, L.P.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALPINE IMMUNE SCIENCES, INC.
Report date May 18, 2024 · Filed May 21, 2024
Jointly reported with Cui Xiangmin, Decheng Capital Management III (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-05-18 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-05-18 · Other · Disposed 6,582,380 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Xiangmin Cui is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-05-18 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-05-18 · Other · Disposed 1,735,544 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F4: These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2029-01-17 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2031-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-02 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-01-02 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2034-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F9: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3: These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Xiangmin Cui is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F4: These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.
F9: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.
BeyondSpring Inc.
Report date October 16, 2025 · Filed October 21, 2025
Jointly reported with Decheng Capital Management III (Cayman), LLC, Decheng Capital China Life Sciences USD Fund II, L.P., Decheng Capital Management II (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin
Section 16 reporting ended · disclosed 2025-10-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital China Life Sciences USD Fund III, L.P. | 1,518,893 |
Last balance in matching sequence
After 2025-10-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-10-16 · Sale · Disposed 85,798 · Balance 1,564,406 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 2 · 2025-10-17 · Sale · Disposed 45,513 · Balance 1,518,893 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital China Life Sciences USD Fund II, L.P. | 1,617,409 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,617,409 F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital Global Healthcare Fund (Master), LP | 891,734 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 891,734 F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Cue Health Inc.
Report date September 28, 2021 · Filed September 30, 2021
Jointly reported with Decheng Capital Management III (Cayman), LLC
Section 16 reporting ended · disclosed 2021-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,192,468 |
Reported balance
After 2021-09-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-28 · Conversion · Acquired 8,192,468 · Balance 8,192,468 F1: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-28 · Conversion · Disposed 8,192,468 · Balance 0 F1: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,152 | $2.28 | $4,906.56 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 13 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 920,798 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 14, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 801 | $2.29 | $1,834.29 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 12 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 922,950 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 11, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 246 | $2.29 | $563.34 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 11 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 923,751 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 10, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 768 | $2.28 | $1,751.04 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 10 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 923,997 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 09, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 252 | $2.27 | $572.04 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 9 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 924,765 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 08, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 9,059 | $2.29 | $20,745.11 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 8 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 925,017 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 02, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 324 | $2.42 | $784.08 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 7 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 934,076 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 01, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 600 | $2.43 | $1,458.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 6 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 934,400 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 23, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 1,700 | $3.09 | $5,253.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 5 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund II, L.P. Disclosed balance after: 1,617,409 F5 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.06 to $3.19 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 20, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 225,217 | $3.16 | $711,685.72 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 4 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund II, L.P. Disclosed balance after: 1,619,109 F4 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.05 to $3.27 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 20, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 60,000 | $3.11 | $186,600.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 935,000 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 18, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 59,253 | $3.17 | $187,832.01 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund II, L.P. Disclosed balance after: 1,844,326 F2 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $3.10 to $3.34 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| June 17, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 5,000 | $3.23 | $16,150.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 995,000 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 17,500 | Not disclosed Strike: $19.00 | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · derivative · entry 8 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires 2034-01-01 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F9 · derivative.exercise_date: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 10,000 | Not disclosed Strike: $7.43 | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · derivative · entry 7 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2033-01-02 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 10,000 | Not disclosed Strike: $13.89 | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · derivative · entry 6 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2032-01-02 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $13.45 | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · derivative · entry 5 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2031-01-03 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $3.62 | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · derivative · entry 4 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2030-01-01 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 20, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | Disposition to issuerStock Option (Right to buy) · Derivative | 7,650 | Not disclosed Strike: $5.70 | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · derivative · entry 3 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,650 shares Expires 2029-01-17 F5 · derivative.exercise_price: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7 · price: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8 · price: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. Read SEC document |
| May 18, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 1,735,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · nonDerivative · entry 2 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F4 · ownership.nature: These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 18, 2024 Filed May 21, 2024 00:08 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 6,582,380 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001626199-24-000095 · wk-form4_1716250094.xml · nonDerivative · entry 1 Cui Xiangmin · CIK 0001487815 · Director · 10% owner Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2 · price: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3 · ownership.nature: These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Xiangmin Cui is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 18:54 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherWarrant (right to buy) · Derivative | 1,234,636 | $0.00 Strike: $12.74 | $0.00 |
DisclosureSEC source: 0001209191-24-002016 · doc4.xml · derivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,234,636 shares Expires 2024-01-18 F1 · ownership.direct: The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 18:54 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | OtherCommon Stock | 1,234,636 | $12.74 | $15,729,262.64 |
DisclosureSEC source: 0001209191-24-002016 · doc4.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,582,380 F1 · ownership.direct: The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 16:46 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantCommon Stock | 1,360,544 | $7.35 | $9,999,998.40 |
DisclosureSEC source: 0001209191-22-051370 · doc4.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,360,544 F2 · ownership.nature: The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 23, 2022 Filed Sep 27, 2022 16:46 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | GrantCommon Stock | 639,456 | $7.35 | $4,700,001.60 |
DisclosureSEC source: 0001209191-22-051370 · doc4.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,347,744 F1 · ownership.direct: The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:48 UTC | Cue Health Inc. HLTH · Entity 87957 | ConversionSeries C-1 Preferred Stock · Derivative | 8,192,468 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-033150 · form4.xml · derivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,192,468 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 28, 2021 Filed Sep 30, 2021 21:48 UTC | Cue Health Inc. HLTH · Entity 87957 | ConversionCommon Stock | 8,192,468 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-033150 · form4.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,192,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document |
| September 17, 2021 Filed Sep 21, 2021 18:39 UTC | ALPINE IMMUNE SCIENCES, INC. ALPN · Entity 90802 | PurchaseCommon Stock | 1,542,553 | $9.40 | $14,499,998.20 |
DisclosureSEC source: 0001626199-21-000118 · wf-form4_163226396485220.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,708,288 F1 · ownership.direct: The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.